[an error occurred while processing this directive]|[an error occurred while processing this directive]
胃食管交界腺癌术后静态IMRT、VMAT和HT剂量学比较
王鑫, 田源, 金晶, 胡志辉, 唐源, 张佳佳, 冯燕茹, 任骅, 李宁, 刘文扬, 李晔雄
100021 北京协和医学院 中国医学科学院肿瘤医院放疗科
A dosimetric comparison of static intensity-modulated radiotherapy,volumetric-modulated arc therapy,and helical tomotherapy after surgery for gastroesophageal junction adenocarcinoma
Abstract： Objective To investigate the effects of different irradiation techniques on dose distribution in target volume and normal tissues after the radical surgery for gastroesophageal junction adenocarcinoma,and to provide the optimal regimen for clinical treatment. Methods A total of 9 patients with gastroesophageal junction adenocarcinoma who underwent radical esophagus-proximal gastrectomy or total gastrectomy were enrolled. The therapeutic regimens of five-field static intensity-modulated radiotherapy (IMRT),volumetric-modulated arc therapy (VMAT),and helical tomotherapy (HT) were designed for each patient,and the dose-volume histogram was used to evaluate the effects of different irradiation techniques on the conformity index (CI) and homogeneity index (HI) of target volume and the surrounding normal tissues. The prescribed dose was 45 Gy at 1.8 Gy/fraction. The patients received oral S-1 as concurrent chemotherapy at a dose of 80 mg/(m2·d) twice a day during radiotherapy. Results Compared with IMRT and VMAT,HT had better CI and HI of the target volume,as well as a better protective effect on the intestinal tract and bone marrow. Compared with IMRT and HT,VMAT had a lower V20 and V30 for the left kidney and a lower V30 for the heart,while IMRT had lower V5 and V10 for both lungs;V20 and mean dose showed no significant differences between the three techniques. HT had the highest mean sub-field hop count,followed by IMRT and VMAT. Conclusions IMRT,VMAT,and HT can meet the clinical requirements,but besides ensuring the best CI and HI of the target volume,HT has a good protective effect on the intestine and spinal cord and can help to reduce the incidence of adverse events in patients.
Wang Xin,Tian Yuan,Jin Jing et al. A dosimetric comparison of static intensity-modulated radiotherapy,volumetric-modulated arc therapy,and helical tomotherapy after surgery for gastroesophageal junction adenocarcinoma[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 255-259.
[1] DeSantis CE,Lin CC,Mariotto AB,et al. Cancer treatment and survivorship statistics,2014[J].CA Cancer J Clin,2014,64(4):252-271.DOI:10.3322/caac.21235. [2] NCCN guidelines panel. National comprehensive cancer network guidelines in oncology (NCCN guidelines).Esophageal and esophagogastric junction cancers.2015.Version 3,2015-03-23[DB/OL]. http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. [3] Japanese classification of gastric carcinoma:3rd English edition[J].Gastric Cancer,2011,14(2):101-112.DOI:10.1007/s10120-011-0041-5. [4] Mell LK,Kochanski JD,Roeske JC,et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,66(5):1356-1365.DOI:10.1016/j.ijrobp.2006.03.018. [5] Smalley SR,Benedetti JK,Haller DG,et al. Updated analysis of SWOG-directed intergroup study 0116:a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J].J Clin Oncol,2012,30(19):2327-2333.DOI:10.1200/JCO.2011.36.7136. [6] Macdonald JS,Smalley SR,Benedetti J,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J].N Engl J Med,2001, 345(10):725-730. DOI:10.1056/NEJMoa010187. [7] Lee J,Lim do H,Kim S,et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial[J].J Clin Oncol,2012,30(3):268-273.DOI:10.1200/JCO.2011.39.1953. [8] Park SH,Sohn TS,Lee J,et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer:final report of the adjuvant chemoradiotherapy in stomach tumors trial,including survival and subset analyses[J].J Clin Oncol,2015,33(28):3130-3136.DOI:10.1200/JCO.2014.58.3930. [9] 王鑫,金晶,李晔雄,等.局部晚期胃癌术后卡培他滨同期调强放疗的Ⅰ期临床研究[J].中华放射肿瘤学杂志,2013,22(5):343-346.DOI:10.3760/cma.j.issn.1004-4221.2013.05.001. Wang X,Jin J,Li YX,et al. Phase Ⅰtrial of postoperative concurrent capecitabine and intensity-modulated radiotherapy for locally advanced gastric cancer[J].Chin J Radiat Oncol,2013,22(5):343-346.DOI:10.3760/cma.j.issn.1004-4221.2013.05.001. [10] Hu W,Wang J,Li G,et al. Investigation of plan quality between RapidArc and IMRT for gastric cancer based on a novel beam angle and multicriteria optimization technique[J].Radiother Oncol,2014,111(1):144-147.DOI:10.1016/j.radonc.2014.01.024. [11] Li Z,Zeng J,Wang Z,et al. Dosimetric comparison of intensity modulated and volumetric arc radiation therapy for gastric cancer[J].Oncol Lett,2014,8(4):1427-1434.DOI:10.3892/ol.2014.2363. [12] Wang X,Li G,Zhang Y,et al. Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer:dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT)[J].Med Dosim,2013,38(4):395-400.DOI:10.1016/j.meddos.2013.04.007. [13] Wieland P,Dobler B,Mai S,et al. IMRT for postoperative treatment of gastric cancer:covering large target volumes in the upper abdomen:a comparison of a step-and-shoot and an arc therapy approach[J].Int J Radiat Oncol Biol Phys,2004,59(4):1236-1244. DOI:10.1016/j.ijrobp.2004.02.051 [14] Dahele M,Skinner M,Schultz B,et al. Adjuvant radiotherapy for gastric cancer:a dosimetric comparison of 3-dimensional conformal radiotherapy,tomotherapy and conventional intensity modulated radiotherapy treatment plans[J].Med Dosim,2010,35(2):115-121.DOI:10.1016/j.meddos.2009.03.003. [15] Zhang T,Liang ZW,Han J,et al. Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer[J].Radiat Oncol,2015,10(1):114-121.DOI:10.1186/s13014-015-0420-x. [16] Fiorino C,Alongi F,Perna L,et al. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer[J].Int J Radiat Oncol Biol Phys,2009,75(1):29-35.DOI:10.1016/j.ijrobp.2008.10.086. [17] Barillot I,Tavernier E,Peignaux K,et al. Impact of post operative intensity modulated radiotherapy on acute gastro-intestinal toxicity for patients with endometrial cancer:results of the phase Ⅱ RTCMIENDOMETRE French multicentre trial[J].Radiother Oncol,2014,111(1):138-143.DOI:10.1016/j.radonc.2014.01.018. [18] Rodel C,Liersch T,Becker H,et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer:initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial[J].Lancet Oncol,2012,13(7):679-687.DOI:10.1016/S1470-2045(12)70187-0. [19] van Hagen P,Hulshof MC,van Lanschot JJ,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088. [20] Lujan AE,Mundt AJ,Yamada SD,et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy[J].Int J Radiat Oncol Biol Phys,2003,57(2):516-521. DOI:10.1016/S0360-3016(03)00521-2. [21] Ahmed RS,Kim RY,Duan J,et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk[J].Int J Radiat Oncol Biol Phys,2004,60(2):505-512. DOI:10.1016/j.ijrobp.2004.03.035. [22] Mell LK,Schomas DA,Salama JK,et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy[J].Int J Radiat Oncol Biol Phys,2008,70(5):1431-1437.DOI:10.1016/j.ijrobp.2007.08.074. [23] Martin S,Chen JZ,Rashid DA,et al. Dosimetric comparison of helical tomotherapy,RapidArc,and a novel IMRT & Arc technique for esophageal carcinoma[J].Radiother Oncol,2011,101(3):431-437.DOI:10.1016/j.radonc.2011.08.030.
2016, Vol. 25 
